Small-molecule inhibitors of PDE-IV and -VII in the treatment of respiratory diseases and chronic inflammation

• GIEMBYCZ MA: Phosphodiesterase 4 inhibitors and the treatment of asthma; where we are now and where do we go from here? Drugs (2000) 59:193-212.
   PubMed Web of Science ®Google Scholar
• GIEMBYCZ MA: Development status of second-generation PDE4 inhibitors forasthma and COPD: the story so far? Monaldi. Arch. Chest Dis. (2002) 57:48-64.
   PubMedGoogle Scholar
• SCOTT AI, PERINI AF, SHERING PA, WHALLEY LJ: In-patient major depression: is rolipram as effective as apytriptyline? Eur. J. Clin. Pharmacol. (1991) 40(2):127-129.
   PubMed Web of Science ®Google Scholar
• LOSCO PE, EVANS EW, BARAT SA et al.: the toxicity of SCH 351591, a novel phosphodiesterase 4B inhibitor, in cynomolgus monkeys. Toxicol. Pathol. (2004) 32(3):295-308.
   PubMed Web of Science ®Google Scholar
• MECKLENBERG L, HEUSER A, JUENGLING T et al.: Mesentritis precedes vasculitis in the rat mesentry after subacute administration of a phosphodiesterase type 4 inhibitor. Toxicol. Lett. (2006) 163(1):54-64.
   PubMed Web of Science ®Google Scholar
• WALLACE DA, JOHNSTON LA, HUSTON E et al.: Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterases gene. Mol. Pharmacol. (2005) 67:1920-1934.
   PubMed Web of Science ®Google Scholar
• HUSTON E, LUMB S, RUSSELL A et al.: Molecular cloning and transient expression in COS cells of a novel human PDE4B cAMP specific phosphodiesterase HSPDE4B3. Biochem. J. (1997) 328(Part 2):549-558.
   PubMed Web of Science ®Google Scholar
• RENA G, BEGG F, ROSS A et al.: Molecular cloning, genomic positioning, promoter identification and characterization of the novel cAMP specific phosphodiesterase PDE4A10. Mol. Pharmacol. (2001) 59:995-1011.
   Google Scholar
• JIN SL, CONTI M: Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl. Acad. Sci. USA (2002) 99(11):7628-7633.
   PubMed Web of Science ®Google Scholar
• LIPWORTH BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 365(9454):167-175.
   PubMed Web of Science ®Google Scholar
• ROCQUE WJ, TAIN J, WISEMAN JS et al.: Human recombinant phosphodiesterase 4B2B binds (R) – rolipram at a single site with two affinities. Biochemistry (1997) 36(46):14250-14261.
   PubMed Web of Science ®Google Scholar
• BARNETTE MS, BARTUS JO, BURMAN M et al.: Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competetion for [3H] rolipram binding. J. Biochem. Pharmacol. (1996) 51(7):949-956.
   PubMed Web of Science ®Google Scholar
• ROBICHAUD A, STAMATIOU PB, JIN SL et al.: Deletion of phoshodiesterase 4D in mice shortens α(2)-adrenoceptor mediated anesthesia, a behavioural correlate of emesis. J. Clin. Invest. (2002) 110(7):1045-1052.
   PubMed Web of Science ®Google Scholar
• LEHNART SE, WEHRENS XHT, REIKEN S et al.: Phoshodiesterase 4D deficiency in the ryanodine receptor complex promotes heart failure and arrhythmias. Cell (2005) 123:25-35.
   PubMed Web of Science ®Google Scholar
• GIEMBYCZ MA: Phosphodiesterase-4 selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. (2005) 2:333-336.
   Google Scholar
• RABE KF, BATEMAN ED, O'DONNEL D, WITTE S, BREDEBBROKER D, BETHKE TD: Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomized controlled trial. Lancet (2005) 366(9485):563-571.
   PubMed Web of Science ®Google Scholar
• SABINA AA: Roflumilast for the treatment of chronic obstructive pulmonary disease. Curr. Opin. Investig. Drugs (2006) 7(5):412-417.
   PubMed Web of Science ®Google Scholar
• LEICHTL S, SCHMID-WIRLITSCH C, BREDENBROKER D et al.: Dose-related efficacy of once-daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in asthma. Am. J. Respir. Crit. Care Med. (2002) 165(8):A185.
   PubMed Web of Science ®Google Scholar
• VAN SCHALKWYK E, STRYDOM K, WILLIAMS Z et al.: Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol. (2005) 116:292-298.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN SB, GUIDER A, FORSTER CJ et al.: 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J. Med. Chem. (1998) 41(6):821-835.
   PubMed Web of Science ®Google Scholar
• COMPTON CH, CUBB J, NEIMAN R et al.: Cilomilast a selective PDE4 inhibitor for the treatment of patients with chronic obstructive pulmonary disease: a randomized dose ranging study. Lancet (2001) 358:265-270.
   PubMed Web of Science ®Google Scholar
• COMPTON C, EDELSON J, CEDAR E et al.: Cilomast (Ariflo) 15 mg bid safety in a 6-month clinical trial program. 97th American Thoracic Society Meeting. San Francisco, USA (18 – 23 May 2001).
   Google Scholar
• GEIMBYCZ MA: An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br. J. Clin. Pharmacol. (2006):1-15.
   PubMedGoogle Scholar
• SCHAFER P: CC-10004: a novel PDE4 inhibitor with an improved therapeutic index. SMI Conference – Chronic Obstructive Pulmonary Disorders. London, UK (10 – 11 March 2004).
   Google Scholar
• ROSEN J, MILLER W, HE M et al.: A novel PDE4 inhibitory agent with endothelial cell specific activity. Proc. Am. Assoc. Cancer Res. (2004) 45:(Abstract 2372).
   Google Scholar
• KHOBZAOUI M, GUTKE HJ, BURNET M: Cc-10004. Curr. Opin. Investig. Drugs (2005) 6(5):518-525.
   PubMedGoogle Scholar
• TAKEDA H, AL E: Pharmacological profile of Ono-6126, a novel phosphodiesterase 4 (PDE4) inhibitor. 98th International Conference of the American Thoracic Society. Atlanta, USA (17 – 22 May 2002).
   Google Scholar
• FURUIE H, NAKAGAWA S, KAWASHIMA M, AL E: Suppressive effect of novel phosphodiesterase 4 (PDE4) inhibitor Ono-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects. Eur. Respir. J. (2003) (Suppl. 45):(Abstract 2557).
   Google Scholar
• VAKKALANKA S: The pharmacological and safety profile of the PDE4 inhibitor GRC-3886. 14th Annual European Respiratory Society Congress. Glasgow, UK (4 – 8 September 2004).
   Google Scholar
• DUPLANTIER AJ, BACHERT EL, CHENG CB et al.: SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]1,2,4-triazolo[4,3-α]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J. Med. Chem. (2007) 50(2):344-349.
   PubMed Web of Science ®Google Scholar
• DRAHEIM R, EGERLAND U, RUNDFELDT C: Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. J. Pharmacol. Exp. Ther. (2004) 308(2):555-563.
   PubMed Web of Science ®Google Scholar
• HANS-JURGEN G, JAN-HINRICH G, MOUSSA K, THEJAVATHI RG, MICHAEL B: AWD-12-281 (inhaled) elbion/GlaxoSmithKline. Curr. Opin. Investig. Drugs (2005) 6(11):1149-1158.
   PubMedGoogle Scholar
• MICHAELI T, BLOOM TG, MARTINS T et al.: Isolation and characterizaton of a previously undetected cAMP specific phosphodiesterase by complementation of a cAMP phosphodiesterase deficient Saccharomyces cerevisiae. J. Biol. Chem. (1993) 268:12925-12932.
   PubMed Web of Science ®Google Scholar
• HAN P, ZHU XY, MICHAELI T: Alternative splicing of the high affinity cAMP specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J. Biol. Chem. (1997) 272:16152-16157.
   PubMed Web of Science ®Google Scholar
• HETMAN JM, SODERLING SH, GLAVAS NA, BEAVO JA: 1. Cloning and characterization of PDE7B, a cAMP specific phosphodiesterase. Proc. Natl. Acad. Sci. USA (2000) 97:472-476.
   PubMed Web of Science ®Google Scholar
• GIEMBYCZ MA, CORRIGAN CJ, SEYBOLD J, NEWTON R, BARNES PJ: Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4 and CD8 T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. (1996) 118:1945-1958.
   PubMed Web of Science ®Google Scholar
• LI L, YEE C, BEAVO JA: CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science (1999) 283(5403):848-851.
   PubMed Web of Science ®Google Scholar
• YANG G, MCINTYRE KW, TOWNSEND RM et al.: Phosphodiesterase 7A-deficient mice have functional T cells. J. Immunol. (2003) 171(12):6414-6420.
   PubMed Web of Science ®Google Scholar
• SMITH SJ, CIESLINSKI LB, NEWTON R et al.: Discovery of BRL 50481 [3 (N,N-dimethylsulfonamido)4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol. Pharmacol. (2004) 66(6):1679-1689.
   PubMed Web of Science ®Google Scholar
• PITTS WJ, VACCARO W, HUYNH T et al.: Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg. Med. Chem. Lett. (2004) 14:2955-2958.
   PubMed Web of Science ®Google Scholar
• KEMPSON J, MARINIER A, DODIER M et al.: Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and structure-activity relationships. Bioorg. Med. Chem. Lett. (2005) 15:1829-1833.
   PubMed Web of Science ®Google Scholar
• GUO J, CARLSEN M, BARBOSA J: Identification and SAR of potent inhibitors of phosphodiesterase 7 (PDE7). 228th ACS Meeting. Philadelphia, USA (22 – 26 August 2004).
   Google Scholar
• BARNES MJ, COOPER N, DAVENPORT RJ et al.: Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg. Med. Chem. Lett. (2001) 11(8):1081-1083.
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, CASTRO A, GIL C et al.: Benzyl derivatives of 2,1,3-benzo- and benzothieno [3,2-a] thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. J. Med. Chem. (2000) 43:683-689.
   PubMed Web of Science ®Google Scholar
• CASTRO A, ABASOLO MI, GIL C, SEGARRA V, MARTINEZ A: CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno [3,2-a] thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. Eur. J. Med. Chem. (2001) 36:333-338.
   PubMed Web of Science ®Google Scholar
• VERGNE F, BERNARDELLI P, LORTHIOIS E et al.: Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. 1. Design, synthesis and structure-activity relationship studies. Bioorg. Med. Chem. Lett. (2004) 14:4607-4613.
   PubMed Web of Science ®Google Scholar
• VERGNE F, BERNARDELLI P, LORTHIOIS E et al.: Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. 2. Metabolism directed optmization studies towards orally bioavailable derivatives. Bioorg. Med. Chem. Lett. (2004) 14:4615-4621.
   PubMed Web of Science ®Google Scholar
• LORTHIOIS E, BERNARDELLI P, VERGNE F et al.: Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1. Bioorg. Med. Chem. Lett. (2004) 14:4623-4626.
   PubMed Web of Science ®Google Scholar
• BERNARDELLI P, LORTHIOIS E, VERGNE F et al.: Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2. Optimization of 5,8-disubstituted derivatives. Bioorg. Med. Chem. Lett. (2004) 14:4627-4631.
   PubMed Web of Science ®Google Scholar
• HUNT H: A novel class of PDE inhibitors. Trends Med. Chem. (2000).
   Google Scholar
• BROWN H: IDDB Meeting Report Trends in medicinal chemistry – SMR symposium-Glaxo Wellcome Research & Development,Stevenage UK. (30 November 2000).
   Google Scholar
• YAMAMOTO S, SUGAHARA S, IKEDA K, SHIMIZU Y: Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models. Eur. J. Pharm. (2006) 550(1-3):166-172.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO S, SUGAHARA S, NAITO R et al.: The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. Eur. J. Pharm. (2006) 541(1-2):106-114.
   PubMed Web of Science ®Google Scholar

Patents

• DARWIN DISCOVERY LTD (GB); DYKE HAZEL JOAN: WO200068230 (2000).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: PITTS WILLIAM JOHN: WO2002088079 (2002).
   Google Scholar
• PATENT NUMBER: PA175052.
   Google Scholar
• PFIZER INC.: WO2006092691 (2006).
   Google Scholar
• DAIICHI ASUBIO PHARMA CO. LTD: WO2004111053 (2004).
   Google Scholar
• DAIICHI ASUBIO PHARMA CO. LTD: WO2004111054 (2004).
   Google Scholar
• ALTANA PHARMA AG: WO200240449 (2002).
   Google Scholar
• ALTANA PHARMA AG: WO200240450 (2002).
   Google Scholar
• MERCK PATENT GMBH: DE19953024 (2001).
   Google Scholar
• MERCK PATENT GMBH: DE19953025 (2001).
   Google Scholar
• MERCK PATENT GMBH: DE19954707 (2001).
   Google Scholar
• MERCK PATENT GMBH: WO200129049 (2001).
   Google Scholar
• MERCK PATENT GMBH: WO2003055882 (2003).
   Google Scholar
• WARNER-LAMBERT CO. LLC: WO2003082839 (2003).
   Google Scholar
• ALMIRALL PRODESFARMA SA: WO2004065391 (2004).
   Google Scholar
• BAYER CORP.: WO2002088138 (2002).
   Google Scholar
• ALTANA PHARMA AG: WO2002085906 (2002).
   Google Scholar
• ORTHO-MCNEIL PHARMACEUTICAL, INC.: WO2002085894 (2002).
   Google Scholar
• JOHNSON & JOHNSON: US040082578 (2004).
   Google Scholar
• DAIICHI ASUBIO PHARMA CO. LTD: WO2006004040 (2006).
   Google Scholar

Websites

• http://www.datamonitor.com/~90c3cffcaf0546f7ad089c97929631c8~/companies/company/?pid_E915DFB3-6FBF-4C67-AE8F-29EB1160FC4C&nid_816AB3F2-982C
   Google Scholar
• http://www.pharmaprojects.com Pharmaprojects © Informa UK Ltd. 2007.
   Google Scholar